Go to deals
Food & Beverage

First Capital has completed an accelerated bookbuilding of 1.98% of Orsero’s share capital

September 2025 — Orsero S.p.A. has successfully completed an accelerated bookbuilding of 1.98% of its share capital, sold by First Capital, for a total deal value of US$7.2 million.

Orsero specializes in the import and distribution of fresh fruits and vegetables. Its operations include sourcing, shipping, ripening, logistics and marketing.

Our role in the transaction

Oaklins Italy’s parent company, Banca Akros, acted as the sole bookrunner in this transaction.

Talk to the deal team

Giulio Greco

Managing Director
Milan, Italy
Oaklins Italy

Giuliano Altieri

Director
Milan, Italy
Oaklins Italy

Nicola Biancoli

Associate
Milan, Italy
Oaklins Italy

Rita Vizzi

Associate
Milan, Italy
Oaklins Italy

Related deals

Bolster Investment Partners has secured debt financing for the acquisition of Royal Taste Company
Private Equity | Food & Beverage

Bolster Investment Partners has secured debt financing for the acquisition of Royal Taste Company

Bolster Investment Partners has partnered with Royal Taste Company, a leading Dutch custom signature coffee platform offering end-to-end sourcing, blending, roasting, packaging and delivery services. The partnership marks an important next step in Royal Taste Company’s growth trajectory, focused on further geographical expansion, commercial development and selective strategic acquisitions.

Learn more
SRT Marine has completed a placing and subscription
TMT

SRT Marine has completed a placing and subscription

SRT Marine Systems plc has announced an equity raise of at least US$22 million at US$1.10 per share representing a 5.75% discount, through a US$19.4 million accelerated bookbuild placing and a US$2 million subscription by Ocean Infinity, alongside a separate retail offer of up to US$1.3 million.

Learn more
IXICO has completed a fundraising
Healthcare

IXICO has completed a fundraising

IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.

Learn more